## 10-Deacetyltaxol: A Promising Anticancer Agent
**10-Deacetyltaxol** is a **synthetic analog of the naturally occurring anti-cancer drug, Taxol (paclitaxel)**. It is a promising compound for research due to its **unique properties and potential therapeutic benefits**.
**Here's a breakdown:**
* **Structure:** 10-Deacetyltaxol differs from Taxol by the absence of an acetyl group at the 10-position. This seemingly small change significantly alters its properties.
* **Properties:** Compared to Taxol, 10-Deacetyltaxol exhibits:
* **Increased water solubility:** This allows for better drug delivery and potentially less severe side effects.
* **Enhanced biological activity:** It shows improved anti-cancer activity in some cell lines compared to Taxol.
* **Reduced toxicity:** In some studies, it has been shown to be less toxic than Taxol.
* **Research Significance:** 10-Deacetyltaxol holds promise as a:
* **More effective anti-cancer agent:** Its enhanced activity could lead to better treatment outcomes.
* **Alternative to Taxol:** Its improved solubility and potentially lower toxicity could make it a preferred choice for some patients.
* **Platform for drug development:** Its structural modifications could inspire further research into new, more potent and less toxic Taxol analogs.
**Key points to note:**
* 10-Deacetyltaxol is still under research and development. It is not yet approved for clinical use.
* While promising, further research is necessary to understand its full potential and limitations.
* Extensive clinical trials are required to assess its efficacy and safety in human patients.
**Overall, 10-Deacetyltaxol represents a significant development in the fight against cancer. Its improved properties and potential benefits make it a valuable tool for research and a promising candidate for future drug development.**
## 10-Deacetyltaxol: A Powerful Anti-Cancer Agent with Research Potential
10-Deacetyltaxol is a **semi-synthetic analog** of the natural product **taxol**, a powerful anti-cancer drug derived from the Pacific Yew tree.
Here's what makes it significant in research:
**1. Improved Pharmacological Properties:**
* **Enhanced Water Solubility:** Unlike taxol, 10-deacetyltaxol is more soluble in water, which is a major advantage for its potential use in drug development. This improved solubility means it can be more easily formulated and delivered to the body, potentially increasing its efficacy and reducing side effects.
* **Increased Stability:** 10-deacetyltaxol exhibits better stability in different environments compared to taxol. This enhanced stability allows for easier storage and handling, making it more practical for research and potential clinical applications.
**2. Anti-Cancer Activity:**
* **Similar Mechanism of Action:** 10-deacetyltaxol shares the same anti-cancer mechanism as taxol. It **inhibits microtubule depolymerization**, effectively stopping cell division in cancerous cells and causing their death.
* **Potentially Improved Efficacy:** Studies have shown that 10-deacetyltaxol might be more effective against certain types of cancer than taxol, particularly in cases where drug resistance has emerged. This makes it a promising candidate for exploring new treatment options for cancer.
**3. Research Applications:**
* **Drug Development:** 10-deacetyltaxol is actively being investigated as a potential anti-cancer drug, particularly for treatment-resistant tumors. Its improved solubility and stability make it a more attractive candidate for clinical trials.
* **Mechanism of Action Studies:** Researchers use 10-deacetyltaxol to further understand the complex mechanisms involved in cancer cell division and microtubule dynamics.
* **Targeted Delivery Systems:** The enhanced solubility of 10-deacetyltaxol makes it ideal for developing targeted delivery systems, allowing for precise delivery of the drug to cancerous cells, minimizing side effects.
**Overall:** 10-deacetyltaxol presents a significant advancement in the field of cancer research. Its improved properties compared to taxol, coupled with its potent anti-cancer activity, make it a promising candidate for future drug development and a valuable tool for understanding the complex biology of cancer cells.
10-deacetyltaxol: alkaloid from Taxus wallichiana, structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| Flora | Rank | Flora Definition | Family | Family Definition |
|---|---|---|---|---|
| Taxus | genus | Genus of coniferous yew trees or shrubs, several species of which have medicinal uses. Notable is the Pacific yew, Taxus brevifolia, which is used to make the anti-neoplastic drug taxol (PACLITAXEL).[MeSH] | Taxaceae | A plant family of the order Pinales, class Pinopsida, division TRACHEOPHYTA.[MeSH] |
| Taxus wallichiana | species | [no description available] | Taxaceae | A plant family of the order Pinales, class Pinopsida, division TRACHEOPHYTA.[MeSH] |
| Taxus | genus | Genus of coniferous yew trees or shrubs, several species of which have medicinal uses. Notable is the Pacific yew, Taxus brevifolia, which is used to make the anti-neoplastic drug taxol (PACLITAXEL).[MeSH] | Taxaceae | A plant family of the order Pinales, class Pinopsida, division TRACHEOPHYTA.[MeSH] |
| Taxus wallichiana | species | [no description available] | Taxaceae | A plant family of the order Pinales, class Pinopsida, division TRACHEOPHYTA.[MeSH] |
| ID Source | ID |
|---|---|
| PubMed CID | 155831 |
| CHEMBL ID | 302324 |
| SCHEMBL ID | 13043169 |
| MeSH ID | M0098911 |
| PubMed CID | 24791029 |
| CHEMBL ID | 1560237 |
| MeSH ID | M0098911 |
| Synonym |
|---|
| 10-deacetyltaxol |
| CHEMBL302324 |
| deacetyltaxol |
| 78432-77-6 |
| 10-deacetyl-paclitaxel |
| benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1h-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2ar-(2aalpha, |
| b77r96ljlk , |
| 10-deacetyl-7-epi-taxol |
| unii-b77r96ljlk |
| S3933 |
| 111149-94-1 |
| 10-desacetyl paclitaxel |
| 10-deacetylpaclitaxel |
| 10-desacetyltaxol |
| 10-o-deacetylpaclitaxel |
| 10-desacetylpaclitaxel |
| paclitaxel impurity g [ep impurity] |
| 4-(acetyloxy)-13alpha-[[(2r,3s)-3-benzamido-2-hydroxy-3-phenylpropanoyl]oxy]-1,7beta,10beta-trihydroxy-9-oxo-5beta,20-epoxytax-11-en-2alpha-yl benzoate |
| benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1h-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, [2ar-[2aalpha, |
| SCHEMBL13043169 |
| TYLVGQKNNUHXIP-MHHARFCSSA-N |
| 10-deacetyl taxol |
| 7-epi-10-deacetyl taxol |
| [(1s,2s,3r,4s,7r,9s,10s,12r,15s)-4-acetyloxy-15-[(2r,3s)-3-benzamido-2-hydroxy-3-phenylpropanoyl]oxy-1,9,12-trihydroxy-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.03,10.04,7]heptadec-13-en-2-yl] benzoate |
| AKOS030242787 |
| mfcd01075780 |
| AS-57909 |
| 10-deacetyl paclitaxel |
| 7-epi-10-deacetyl-taxol |
| 10-deacetyltaxol a |
| deacetyltaxol10-deacetyltaxol |
| bkr , |
| 10-dat |
| deacetyl paclitaxel |
| CS-0016811 |
| HY-N1391 |
| CCG-270505 |
| Q27274453 |
| DTXSID00999763 |
| n-(3-{[4-(acetyloxy)-2-(benzoyloxy)-1,7,10-trihydroxy-9-oxo-5,20-epoxytax-11-en-13-yl]oxy}-2-hydroxy-3-oxo-1-phenylpropyl)benzenecarboximidic acid |
| (2beta,5beta,7alpha,8alpha,10alpha,13alpha)-4-(acetyloxy)-13-({(2r,3s)-3-[(benzenecarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1,7,10-trihydroxy-9-oxo-5,20-epoxytax-11-en-2-yl benzoate |
| PD088403 |
| 10-deacetyl-7-epitaxol |
| MLS001097661 |
| smr000578100 |
| NCGC00247430-01 |
| HMS2268E21 |
| CHEMBL1560237 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " The developed method was successfully applied to the pharmacokinetic study of the seven taxoids in rat plasma after oral administration of the crude extract of the twigs and leaves of Taxus yunnanensis." | ( Simultaneous determination of seven taxoids in rat plasma by UPLC-MS/MS and pharmacokinetic study after oral administration of Taxus yunnanensis extracts. Bai, X; Gou, X; Hou, X; Huang, M; Jin, J; Li, D; Liu, B; Zhong, G, 2015) | 0.42 |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Chain A, Beta-lactamase | Escherichia coli K-12 | Potency | 17.7828 | 0.0447 | 17.8581 | 100.0000 | AID485341 |
| Chain A, Ferritin light chain | Equus caballus (horse) | Potency | 8.9125 | 5.6234 | 17.2929 | 31.6228 | AID485281 |
| glp-1 receptor, partial | Homo sapiens (human) | Potency | 0.3162 | 0.0184 | 6.8060 | 14.1254 | AID624417 |
| ATAD5 protein, partial | Homo sapiens (human) | Potency | 0.2592 | 0.0041 | 10.8903 | 31.5287 | AID504467 |
| TDP1 protein | Homo sapiens (human) | Potency | 0.0556 | 0.0008 | 11.3822 | 44.6684 | AID686978; AID686979 |
| Smad3 | Homo sapiens (human) | Potency | 15.8489 | 0.0052 | 7.8098 | 29.0929 | AID588855 |
| 67.9K protein | Vaccinia virus | Potency | 0.3162 | 0.0001 | 8.4406 | 100.0000 | AID720579 |
| glucocerebrosidase | Homo sapiens (human) | Potency | 14.1254 | 0.0126 | 8.1569 | 44.6684 | AID2101 |
| IDH1 | Homo sapiens (human) | Potency | 0.2060 | 0.0052 | 10.8652 | 35.4813 | AID686970 |
| NPC intracellular cholesterol transporter 1 precursor | Homo sapiens (human) | Potency | 0.2512 | 0.0126 | 2.4518 | 25.0177 | AID485313 |
| ras-related protein Rab-9A | Homo sapiens (human) | Potency | 2.2387 | 0.0002 | 2.6215 | 31.4954 | AID485297 |
| urokinase-type plasminogen activator precursor | Mus musculus (house mouse) | Potency | 1.0000 | 0.1585 | 5.2879 | 12.5893 | AID540303 |
| plasminogen precursor | Mus musculus (house mouse) | Potency | 1.0000 | 0.1585 | 5.2879 | 12.5893 | AID540303 |
| urokinase plasminogen activator surface receptor precursor | Mus musculus (house mouse) | Potency | 1.0000 | 0.1585 | 5.2879 | 12.5893 | AID540303 |
| nuclear receptor ROR-gamma isoform 1 | Mus musculus (house mouse) | Potency | 12.9244 | 0.0079 | 8.2332 | 1,122.0200 | AID2546; AID2551 |
| geminin | Homo sapiens (human) | Potency | 8.1995 | 0.0046 | 11.3741 | 33.4983 | AID624297 |
| histone acetyltransferase KAT2A isoform 1 | Homo sapiens (human) | Potency | 0.7943 | 0.2512 | 15.8432 | 39.8107 | AID504327 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1371027 | Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 72 hrs by WST-8 dye based assay | 2017 | Journal of natural products, 04-28, Volume: 80, Issue:4 | α-Glucosidase Inhibitory and Cytotoxic Taxane Diterpenoids from the Stem Bark of Taxus wallichiana. |
| AID299265 | Ratio of permeability from basolateral to apical over apical to basolateral side of the MDR-MDCK cells at 5 uM after 120 mins | 2007 | Bioorganic & medicinal chemistry letters, Jul-01, Volume: 17, Issue:13 | Paclitaxel C-10 carbamates: potential candidates for the treatment of neurodegenerative tauopathies. |
| AID230958 | Ratio of the concentration leading to a 50% inhibition of the rate of pig brain microtubule disassembly to that of taxol (0.4 uM) was determined | 1991 | Journal of medicinal chemistry, Mar, Volume: 34, Issue:3 | Relationships between the structure of taxol analogues and their antimitotic activity. |
| AID259943 | Activity in tubulin assembly assay relative to paclitaxel | 2006 | Bioorganic & medicinal chemistry letters, Feb, Volume: 16, Issue:3 | Single-site chemical modification at C10 of the baccatin III core of paclitaxel and Taxol C reduces P-glycoprotein interactions in bovine brain microvessel endothelial cells. |
| AID1371026 | Inhibition of Saccharomyces cerevisiae alpha-glucosidase using p-nitrophenyl-alpha-D-glucopyranoside substrate incubated for 30 mins | 2017 | Journal of natural products, 04-28, Volume: 80, Issue:4 | α-Glucosidase Inhibitory and Cytotoxic Taxane Diterpenoids from the Stem Bark of Taxus wallichiana. |
| AID299263 | Apparent permeability from apical to basolateral side in MDR-MDCK cells overexpressing human p-glycoprotein at 5 uM after 120 mins | 2007 | Bioorganic & medicinal chemistry letters, Jul-01, Volume: 17, Issue:13 | Paclitaxel C-10 carbamates: potential candidates for the treatment of neurodegenerative tauopathies. |
| AID399147 | In vivo antitumor activity against mouse P388 cells at 16 mg/kg relative to control | |||
| AID398248 | Cytotoxicity against human KB cells | 2004 | Journal of natural products, Feb, Volume: 67, Issue:2 | Biological activity and chemistry of taxoids from the Japanese yew, Taxus cuspidata. |
| AID299262 | Cytotoxicity against HEK293 cells | 2007 | Bioorganic & medicinal chemistry letters, Jul-01, Volume: 17, Issue:13 | Paclitaxel C-10 carbamates: potential candidates for the treatment of neurodegenerative tauopathies. |
| AID299264 | Apparent permeability from basolateral to apical side in MDR-MDCK cells overexpressing human p-glycoprotein at 5 uM after 120 mins | 2007 | Bioorganic & medicinal chemistry letters, Jul-01, Volume: 17, Issue:13 | Paclitaxel C-10 carbamates: potential candidates for the treatment of neurodegenerative tauopathies. |
| AID259944 | Cytotoxicity against human breast cancer MCF7 cell line relative to paclitaxel | 2006 | Bioorganic & medicinal chemistry letters, Feb, Volume: 16, Issue:3 | Single-site chemical modification at C10 of the baccatin III core of paclitaxel and Taxol C reduces P-glycoprotein interactions in bovine brain microvessel endothelial cells. |
| AID399145 | Cytotoxicity against human KB cells | |||
| AID1347086 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID1347082 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| AID1347083 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 1 (3.70) | 18.7374 |
| 1990's | 3 (11.11) | 18.2507 |
| 2000's | 7 (25.93) | 29.6817 |
| 2010's | 13 (48.15) | 24.3611 |
| 2020's | 3 (11.11) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.87) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (4.35%) | 6.00% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 1 (4.35%) | 4.05% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 21 (91.30%) | 84.16% |
| Other | 6 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||